Author

A. Jabouille

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

A. Abou-Ammoud· 1 shared A. Pham-Ledart· 1 shared A. Uguen· 1 shared A.-A. Raymond· 1 shared B. Rousseau· 1 shared B. Vergier· 1 shared D. Cyril· 1 shared E. Gerard· 1 shared

Activity by Year

2021-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Abou-Ammoud

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Discoidin domain receptor 2 drives melanoma drug resistance through AXL-dependent phenotype switching

M. Sala, N. Allain, A. Jabouille, E. Henriet, A. Abou-Ammoud, A. Uguen, S. Di-Tommaso, D. Cyril, A.-A. Raymond, J.-W. Dupuy, E. Gerard, N. Dugot-Senant, B. Rousseau, J.-P. Merlio, A. Pham-Ledart, , F. Saltel

This study shows DDR2 drives melanoma drug resistance via AXL-dependent phenotype switching, suggesting DDR inhibition as a potential second-line treatment.

bioRxiv · Mar 26, 2021 · PreprintCancer Biology